

References for CEQUA® (cyclosporine ophthalmic solution) 0.09%

CEQUA FY2025 Congress E-Blast

References:

1. CEQUA prescribing information. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2022.
2. Hovanesian J, Berdy G, Sorensen R. CEQUA's Onset of Action Trial: an Investigation of Cyclosporine 0.09% Speed of Onset in Improving Ocular Surface Health in Dry Eye Patients. Presented at: ASCRS; April 25-28, 2025; Los Angeles, CA.
3. Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. *Ophthalmology*. 2019;126(9):1230-1237.
4. Malhotra R, Devries DK, Luchs J, et al. Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on corneal staining in patients with keratoconjunctivitis sicca: a pooled analysis of phase 2b/3 and phase 3 studies. *Cornea*. 2019;38:1259-1265.
5. Tauber J, Schechter BA, Bacharach J, et al. A phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease. *Clin Ophthalmol*. 2018;12:1921-1929.

Current as of February 13, 2026

© 2026 Sun Pharmaceutical Industries, Inc. All rights reserved. CEQUA is a registered trademark of Sun Pharmaceutical Industries Limited. All other trademarks are the property of their respective owners.

PM-US-CQA-2117 02/2026